Alosetron is used in the research of irritable bowel syndrome (IBS); it acts as a potent and selective 5-HT3 receptor antagonist, blocking 5-HT3-mediated fast depolarization in myenteric and submucosal neurons of guinea pigs (IC50 ~55 nM); it alleviates visceral nociceptive responses to colorectal distension in conscious or anesthetized dogs; it exhibits anti-inflammatory activity; in vivo studies show that alosetron (1 mg/kg, i.p., daily for 6 days) significantly reduces the diarrhea index in rats with TNBS-induced colitis, particularly after the first 2 days of treatment.